#JPM22: High­lights for the year ahead in on­col­o­gy R&D — What's hot, what's not?

3 days ago
R&D

#JPM22 - The gene edit­ing rev­o­lu­tion: Now it's time for hu­man da­ta to de­fine a fast-chang­ing field

3 days ago
R&D

#JPM22 - Deal­mak­ing in 2022: What's Big Phar­ma look­ing for and what is it will­ing to pay?

4 days ago
Deals

#JPM22: The fire­side chat with Take­da CEO Christophe We­ber

4 days ago
Marketing

#JPM22: Catal­ent CEO John Chimin­s­ki with John Car­roll — Our pre­dic­tions for the bio­phar­ma in­dus­try in 2022

5 days ago
Manufacturing

#JPM22: 4 top R&D chiefs dis­cuss the key forces re­shap­ing bio­phar­ma

5 days ago
R&D

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we have so lit­tle of it)

5 days ago
Coronavirus
In Focus

Make or break for Bio­gen: How the na­tion­al cov­er­age de­ci­sion for amy­loid-tar­get­ed Alzheimer’s drugs will shake out

Last week
Pharma

FDA+ roundup: Agency re­struc­tures chief sci­en­tist's of­fice; First vote on Rob Califf as com­mis­sion­er pushed to next week

Last week
FDA+

2021's NDA list in­cludes some ex­tra­or­di­nary ac­com­plish­ments in year #2 of the pan­dem­ic

Last week
Special

‘Dis­ap­point­ing’ Vi­a­Cyte da­ta raise ques­tions about fu­ture of com­pa­ny’s at­tempt­ed di­a­betes cure

4 weeks ago
R&D
Cell/Gene Tx

#ASH21: The Jay Brad­ner in­ter­view: 'We're work­ing up a good­ly num­ber of deal­s'

Last month
Cell/Gene Tx

Video: Hear from End­points' 2021 Women in Bio­phar­ma R&D hon­orees and lis­ten in on our pan­el dis­cus­sion on break­ing the glass ceil­ing

Last month
Special

FDA+ roundup: Re­pub­li­cans will be key for Rob Calif­f's con­fir­ma­tion; Janet Wood­cock and Mar­garet Ham­burg talk FDA and the pan­dem­ic

Last month
FDA+

'We're in': Roche and Genen­tech join forces on a multi­bil­lion-dol­lar dis­cov­ery pact with a brash AI up­start

Last month
Deals
Bioregnum

The 2022 wave com­ing? Top an­a­lyst says Big Phar­ma will have more than $1T avail­able to sat­is­fy its grow­ing ap­petite for biotech M&A

Last month
Deals
Bioregnum

Till­man Gern­gross on Omi­cron: 'It is a grim sit­u­a­tion...we’re go­ing to see a sig­nif­i­cant drop in vac­cine ef­fi­ca­cy'

Last month

Cures 2.0: Bi­par­ti­san House bill would al­low RWE to sat­is­fy con­fir­ma­to­ry tri­al re­quire­ments for ac­cel­er­at­ed ap­provals

2 months ago
FDA+

Ex­clu­sive: Big-name aca­d­e­mics and in­vestors are qui­et­ly prepar­ing a slate of new (epi)genome edit­ing com­pa­nies

2 months ago
Cell/Gene Tx
In Focus

BioN­Tech CEO in­ter­view: On boost­ers, the fu­ture of Covid-19, and the plan to make and ship the next vac­cine in 3 months

2 months ago
People
Coronavirus

The renowned drug hunter, the Wash­ing­ton in­sid­er, the MIT strate­gist: How did one low-pro­file biotech en­list a dream team of top biotech ad­vi­sors?

2 months ago
Bioregnum
Cell/Gene Tx

FDA+ roundup: FDA chief sci­en­tist de­parts to be deputy sur­geon gen­er­al; New trans­paren­cy on on­col­o­gy ac­cel­er­at­ed ap­provals

2 months ago
FDA+

An­ti­sense tech­nol­o­gy changed one dev­as­tat­ing dis­ease. Why has­n't it trans­formed oth­ers?

2 months ago
R&D
In Focus

FDA+ roundup: CDER's break­through des­ig­na­tion re­quests see steep de­cline in 2021; Drug­mak­ers call to ex­pand FDA guid­ance on PD-(L)1 dos­ing

2 months ago
FDA+
1234 Next page Last page